

# DARWIN EU® - Chondrosarcoma: patient demographics, treatments, and survival in the period 2010-2023

**First published:** 16/05/2024

**Last updated:** 26/02/2025

Study

Finalised

## Administrative details

### EU PAS number

EUPAS1000000162

---

### Study ID

1000000162

---

### DARWIN EU® study

Yes

---

### Study countries

- Finland
- France
- Netherlands
- Spain

United Kingdom

---

### **Study description**

This study is aimed to describe demographics, treatments, and overall survival of patients with incident chondrosarcoma, stratified by age, sex, study period, country/database, and, if available, by the AJCC/UICC TNM (Tumour, Nodes, Metastases) classification system of malignant tumors (AJCC/UICC TNM) stage categories and histological grade in 2010-2023.

The specific objectives of this study are:

1. To describe demographic characteristics (age and sex) of patients with chondrosarcoma at the time of diagnosis.
  2. To describe chondrosarcoma treatment options (drug therapy, surgery, and radiation, when available).
  3. To estimate the overall survival of newly diagnosed chondrosarcoma patients during the study period (2010-2023).
- 

### **Study status**

Finalised

## Research institutions and networks

### Institutions

Department of Medical Informatics - Health Data Science, Erasmus Medical Center (ErasmusMC)

Netherlands

**First published:** 03/11/2022

**Last updated:** 02/05/2024

**Institution**

**Educational Institution**

**ENCePP partner**

## Networks

### Data Analysis and Real World Interrogation Network (DARWIN EU®)

- Belgium
- Croatia
- Denmark
- Estonia
- Finland
- France
- Germany
- Greece
- Hungary
- Italy
- Netherlands
- Norway
- Portugal
- Spain
- Sweden
- United Kingdom

**First published:** 01/02/2024

Last updated: 30/04/2025

Network

## Contact details

### Study institution contact

Ilse Schuemie [study@darwin-eu.org](mailto:study@darwin-eu.org)

Study contact

[study@darwin-eu.org](mailto:study@darwin-eu.org)

### Primary lead investigator

Talita Duarte-Salles

Primary lead investigator

## Study timelines

### Date when funding contract was signed

Planned: 20/03/2024

Actual: 20/03/2024

---

### Study start date

Planned: 24/05/2024

Actual: 03/06/2024

---

### Date of final study report

Planned: 07/03/2025

Actual: 07/02/2025

## Sources of funding

- EMA

## Study protocol

[DARWIN EU\\_D2.2.3\\_Protocol\\_P2-C1-003\\_v3.1\\_Chondrosarcoma.pdf](#) (840.73 KB)

## Regulatory

### **Was the study required by a regulatory body?**

Yes

---

### **Is the study required by a Risk Management Plan (RMP)?**

Not applicable

## Methodological aspects

### Study type

### Study type list

#### **Study topic:**

Disease /health condition

---

#### **Study type:**

Non-interventional study

---

#### **Scope of the study:**

Disease epidemiology

**Data collection methods:**

Secondary use of data

---

**Study design:**

A retrospective cohort study of all newly diagnosed chondrosarcoma cases will be conducted.

**Main study objective:**

To describe demographics, treatments, and overall survival of patients with incident chondrosarcoma, stratified by age, sex, study period, country/database, and, if available, by AJCC/UICC TNM stage categories and histological grade in 2010-2023.

The specific objectives of this study are:

1. To describe demographic characteristics (age and sex) of patients with chondrosarcoma at the time of diagnosis.
2. To describe chondrosarcoma treatment with medicines (chemotherapy and biologics) in patients that had undergone or not surgery, radiotherapy, both or neither.
3. To estimate the overall survival of newly diagnosed chondrosarcoma patients during the study period (2010-2023).

## Study Design

**Non-interventional study design**

Cohort

## Study drug and medical condition

## Medical condition to be studied

Chondrosarcoma

## Population studied

### Short description of the study population

The study population will include all individuals with a first diagnosis of chondrosarcoma identified in each database between 01/01/2010 and 31/12/2023. Participants with a diagnosis of cancer (any, excluding non-melanoma skin cancer) or enchondroma before the diagnosis of chondrosarcoma will be excluded.

---

### Age groups

- **Paediatric Population (< 18 years)**

- Preterm newborn infants (0 - 27 days)
- Term newborn infants (0 - 27 days)
- Children (2 to < 12 years)
- Adolescents (12 to < 18 years)

- **Adult and elderly population (≥18 years)**

- Adults (18 to < 65 years)
  - Adults (18 to < 46 years)
  - Adults (46 to < 65 years)
- Elderly (≥ 65 years)
  - Adults (65 to < 75 years)
  - Adults (75 to < 85 years)
  - Adults (85 years and over)

## Study design details

## Setting

This study will use routinely collected health data from 6 nationwide and region-wide databases in 5 European countries.

## Documents

### Study report

[DARWIN EU\\_Report\\_P3-C1-003\\_Chondrosarcoma\\_V2.pdf](#) (1.97 MB)

## Data management

### ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

## Data sources

### Data source(s)

BIFAP - Base de Datos para la Investigación Farmacoepidemiológica en el Ámbito Público (Pharmacoepidemiological Research Database for Public Health Systems)

Hospital District of Helsinki and Uusimaa patient cohort (FinOMOP)

Clinical Practice Research Datalink (CPRD) GOLD

Netherlands Cancer Registry

Clinical Data Warehouse of the Bordeaux University Hospital

## Use of a Common Data Model (CDM)

### **CDM mapping**

Yes

### **CDM Mappings**

#### **CDM name**

OMOP

---

#### **CDM website**

<https://www.ohdsi.org/Data-standardization/>

---

## Data quality specifications

### **Check conformance**

Unknown

---

### **Check completeness**

Unknown

---

### **Check stability**

Unknown

---

### **Check logical consistency**

Unknown

## Data characterisation

## **Data characterisation conducted**

No